Use of Bromhexine and Hydroxychloroquine for Treatment of COVID-19 Pneumonia
Status:
Recruiting
Trial end date:
2020-07-31
Target enrollment:
Participant gender:
Summary
In the current situation it is of great importance to discover a safe, cost-effective and
available treatment strategy in order to limit the rapidly spreading SARS-Cov-2. Recent
studies have shown that hydroxychloroquine could have a role in the treatment of infected
patients. It is however not very likely that hydroxychloroquine alone could be adequate for
treatment of Covid-19 disease. Effective therapy that prevents the virus entrance should
contain at least TMPRSS2 inhibitor or a competitive inhibitor of viral ACE 2 binding. The use
of bromhexine at the dose adequate to selectively inhibit the TMPRSS2, resulting in
preventing of viral entrance via TMPRSS2-specific pathway, coud be an effective treatment of
Covid-19. In our study we would like to explore the therapeutic potential of bromhexin and
hydroxychloroquine in Covid-19 patients.
Hypothesis
1. Combined treatment with bromhexin and hydroxychloroquine shortens the course of disease
in hospitalized Covid-19 patients compared to hydroxychloroquine alone.
2. Combined treatment with bromhexin and hydroxychloroquine lowers the incidence of
secundary pulmonary infections in hospitalized Covid-19 patients compared to
hydroxychloroquine alone.
3. Combined treatment with bromhexin and hydroxychloroquine decreases the need for ICU
admission in hospitalized Covid-19 patients compared to hydroxychloroquine alone.